Skip to content
CompanySight
Company No. 08307830 · Incorporated 26 Nov 2012

Lucis Pharma Ltd

Registered name: LUCIS PHARMA LTD

Part of Primrose Topco Limited group

Lucis Pharma Ltd made £3.5m revenue and £2m profit in the year to 31 Dec 2025.

Lucis Pharma Ltd’s revenue fell 16% to £3.5m in the year to 31 Dec 2025, with £2m profit. The company is classified under “wholesale of pharmaceutical goods” and is based in Leeds; we hold 3 years of its filed accounts.

Full P&L filedSection G · Wholesale and retail trade; repair of motor vehiclesSIC 46460Wholesale of pharmaceutical goods
Status
Active
Location
Leeds, Yorkshire and The Humber
Age
13 yrs · since 2012
Type
Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2025

Key figures

Revenue
£3.5m
Growth ▼16.3%
Profit
£2m
Growth ▼14.8%
Profit margin
57.4%
Gross 69.3%
Employees
—
Change —
Profit / employee
—
 
Profitable streak
3yrs
Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to31 Dec 202331 Dec 202431 Dec 2025
DisclosureFull P&LFull P&LFull P&L
Profit & loss
Revenue (turnover)£10.1m£4.2m£3.5m
Cost of sales−£6.2m−£1.3m−£1.1m
Gross profit£3.9m£2.9m£2.5m
Operating profit£2.5m£2.4m£2m
Profit before tax£2.5m£2.4m£2m
Profit after tax£2.2m£2.4m£2m
Profit (best available)£2.2m£2.4m£2m
Employees (average)13—
Ratios
Profit margin21.9%56.4%57.4%
Gross margin38.9%69.4%69.3%
Revenue per employee£10.1m£1.4m—
Profit per employee£2.2m£795k—
Growth (year on year)
Revenue growth—▼58.1%▼16.3%
Profit growth—▲7.9%▼14.8%
Headcount growth—▲200%—
Balance sheet — indirect signals, not revenue
Net assets———
SourceAccounts · bulk data Apr 2025Accounts · bulk data Apr 2025Accounts · bulk data Mar 2026
Derived from the latest filing

How the business works

Profit margin
57.4%
Profit ÷ revenue.
Gross margin
69.3%
Gross profit ÷ revenue. High for software and services.
Revenue per employee
—
Revenue ÷ average employees.
Profit per employee
—
Profit ÷ average employees.
Cash conversion
—
Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue
—
Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue
—
Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue
—
Money owed by customers. Low = customers pay quickly.
Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets
—
Now —
Cash at bank
—
Now —
Headcount
—
Now —
Deferred income
—
Now —
Fixed assets
—
Now —
Corporate ownership

Group structure

Ownership chain

  1. Primrose Topco Limitedultimate parent75–100%
  2. Primrose Midco 1 Limited75–100%
  3. Rosemont Pharmaceuticals Limited75–100%
  4. Lucis Holdings Limited75–100%
  5. Lucis Pharma Ltdthis company

Bands show the share of ownership each company holds in the one below it.

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Latest figures from accounts for the year to 31 Dec 2025 (profit £2m), from the Companies House accounts bulk data published Mar 2026. Spotted an error? Request a correction.

Updated from Companies House on 12 Oct 2026

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.